Eventide's Healthcare Fund Holds 5.4% Of Agenus In A Passive Position
The fund held 2,446,789 common shares at September's end in the clinical-stage cancer immunotherapy developer.
Eventide Healthcare & Life Sciences Fund held a 5.4% stake in Agenus, which develops immunotherapies for cancer and infectious disease, according to a passive ownership disclosure filed Friday. Its adviser, Eventide Asset Management, reported 2,446,789 common shares measured as of September 30, 2026.
The Fund Holds The Shares
The position belongs to Eventide Healthcare & Life Sciences Fund, a registered investment company. Eventide Asset Management reported the holding through its role as the fund's investment adviser.
Finny Kuruvilla and Robin C. John were also reporting persons for the same 2,446,789-share position. Each reported 5.4% of the common-stock class; those entries describe the same fund holding.
Eventide reported sole authority to vote and dispose of the shares. Kuruvilla and John each reported shared authority over voting and disposal for that position.
The reporting persons certified that the shares were held for ordinary business purposes, without a purpose or effect of changing or influencing Agenus's control. The ownership measurement dates to September's end, while Friday was the disclosure's filing date.
Cancer Drugs Still In Testing
Agenus's main business is immuno-oncology: developing treatments that enlist the immune system against cancer. Its leading antibody drugs, botensilimab and balstilimab, are being tested together in colorectal cancer and other tumor types.
The development program includes a global late-stage trial with the Canadian Cancer Trials Group. Agenus has treated about 1,200 patients with botensilimab, balstilimab or both in early-stage trials.
Neither drug is approved for sale. Patients can receive them through trials and access programs, including a program reimbursed by France's national health system.
Agenus also majority-owns SaponiQx, which develops ingredients that strengthen vaccines' effects. As of December 31, 2025, it owned about 46% of MiNK Therapeutics.
The fund's 5.4% position is in a company whose leading cancer drugs remain in clinical development.
Sources
- SCHEDULE 13G — Eventide Asset Management, LLC re: Agenus Inc (AGEN) — SEC EDGAR
- Agenus Inc. (NASDAQ:AGEN) : Articles :: Law360 — law360.com
- Agenus Inc. (NASDAQ:AGEN) : Ptab Cases :: Law360 — law360.com
- Agenus Inc. (NASDAQ:AGEN) : Cases :: Law360 — law360.com